Hopman Mark sold $102K of BBNX

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Beta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.

Beta Bionics (BBNX) raised $172.5M in a stock offering, selling 7.65M shares at $17.25 each. Underwriters exercised an option for 1.3M more shares. Proceeds will support Mint commercialization, manufacturing, and R&D. J.P. Morgan and others managed the offering.

Beta Bionics (BBNX) received FDA clearance for its Mint patch pump, expanding its insulin delivery portfolio. The company also announced a next-gen 3D Intelligence algorithm under review. BBNX stock surged 15% on the news, despite a 27.2% YTD decline. The FDA clearance opens access to the growing patch pump market and may improve long-term margins.

Beta Bionics received FDA clearance for its Mint tubeless insulin patch pump, planning a U.S. launch in early 2027. The company expects 40% of insured Americans to have pharmacy coverage at launch, rising to 50% within a year. Beta Bionics lowered its 2026 revenue forecast to $121M-$126M, citing potential deferrals as customers wait for Mint. The pump will compete with Insulet's dominant patch pump and Medtronic's upcoming submission.

Beta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.